Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1975 5
1976 6
1977 2
1978 4
1979 4
1980 2
1981 2
1982 2
1983 8
1984 7
1985 7
1986 6
1987 7
1988 9
1989 8
1990 6
1991 15
1992 10
1993 10
1994 7
1995 8
1996 10
1997 10
1998 5
1999 4
2000 5
2001 5
2002 9
2003 8
2005 9
2006 7
2007 4
2008 4
2009 3
2010 4
2011 5
2012 7
2013 3
2014 8
2015 9
2016 8
2017 4
2018 6
2019 4
2020 1
2021 5
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Adult Acute Erythroid Leukemia"
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but responses are limited and transient. Luspatercept promotes late-stage erythroid maturation and has shown durab …
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelody …
Myelodysplastic Syndromes: A New Decade.
Volpe VO, Garcia-Manero G, Komrokji RS. Volpe VO, et al. Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):1-16. doi: 10.1016/j.clml.2021.07.031. Epub 2021 Aug 2. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34544674 Review.
Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supplement. ...In many …
Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely …
Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT.
Ishiyama K, Yamaguchi T, Eto T, Ohashi K, Uchida N, Kanamori H, Fukuda T, Miyamura K, Inoue Y, Taguchi J, Mori T, Iwato K, Morishima Y, Nagamura-Inoue T, Atsuta Y, Sakamaki H, Takami A. Ishiyama K, et al. Leuk Res. 2016 Aug;47:47-53. doi: 10.1016/j.leukres.2016.04.017. Epub 2016 May 12. Leuk Res. 2016. PMID: 27244257
Acute erythroid leukemia (FAB-M6) and acute megakaryoblastic leukemia (FAB-M7) exhibit closely related properties in cells regarding morphology and the gene expression profile. ...Consequently, the factors of age, gender, performance status, kar …
Acute erythroid leukemia (FAB-M6) and acute megakaryoblastic leukemia (FAB-M7) exhibit closely related pr …
Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
El Rassi F, Ward KC, Flowers CR, Heffner LT, Waller EK, Winton EF, Vaughn J, Hill BG, Langston A, Nooka A, Arellano M, Khoury HJ. El Rassi F, et al. South Med J. 2014 Aug;107(8):497-500. doi: 10.14423/SMJ.0000000000000146. South Med J. 2014. PMID: 25084186
OBJECTIVE: We investigated an apparent increase in acute lymphoblastic leukemia (ALL) referrals from northern Georgia to a tertiary care center located in Atlanta. ...Age-adjusted incidence rates were calculated for all of the counties and public health regions and …
OBJECTIVE: We investigated an apparent increase in acute lymphoblastic leukemia (ALL) referrals from northern Georgia to a ter …
Linking GATA2 to myeloid dysplasia and complex cytogenetics in adult myelodysplastic neoplasm and acute myeloid leukemia.
Robbins DJ, Pavletich TS, Patil AT, Pahopos D, Lasarev M, Polaki US, Gahvari ZJ, Bresnick EH, Matson DR. Robbins DJ, et al. Blood Adv. 2024 Jan 9;8(1):80-92. doi: 10.1182/bloodadvances.2023011554. Blood Adv. 2024. PMID: 38029365 Free PMC article.
Patients born with monoallelic GATA2 mutations develop myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML), whereas acquired GATA2 mutations are reported in 3% to 5% of sporadic AML cases. ...Here, we purified a polyclonal anti-GATA2 antibody and generat …
Patients born with monoallelic GATA2 mutations develop myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML), wherea …
Erythroid cell differentiation.
Forget BG, Glass J, Housman D. Forget BG, et al. Hamatol Bluttransfus. 1976;19:109-24. doi: 10.1007/978-3-642-87524-3_12. Hamatol Bluttransfus. 1976. PMID: 1070457
We have reviewed erythroid cell differentiation from two points of view: 1) differences between fetal and adult human red cells with particular reference to alterations which can occur in the normal pattern of erythroid cell development during the course of …
We have reviewed erythroid cell differentiation from two points of view: 1) differences between fetal and adult human red cell …
A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.
Margolskee E, Mikita G, Rea B, Bagg A, Zuo Z, Sun Y, Goswami M, Wang SA, Oak J, Arber DA, Allen MB, George TI, Rogers HJ, Hsi E, Hasserjian RP, Orazi A. Margolskee E, et al. Mod Pathol. 2018 Jun;31(6):873-880. doi: 10.1038/s41379-018-0001-2. Epub 2018 Feb 5. Mod Pathol. 2018. PMID: 29403082 Free article.
Although acute myeloid leukemia with 50% erythroid cells has historically been presumed to represent acute myeloid leukemia with myelodysplasia-related changes, this hypothesis has never been systematically examined. ...Our study is one of the f …
Although acute myeloid leukemia with 50% erythroid cells has historically been presumed to represent acute myelo …
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.
Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP. Wang SA, et al. Mod Pathol. 2016 Oct;29(10):1221-31. doi: 10.1038/modpathol.2016.118. Epub 2016 Jul 15. Mod Pathol. 2016. PMID: 27443511 Free article.
Compared to refractory anemia with excess blasts, acute erythroleukemia patients had higher total bone marrow blasts, lower platelets, hemoglobin, and absolute neutrophil counts, with more patients being assigned a very-poor-karyotype risk and very-high Revised Internation …
Compared to refractory anemia with excess blasts, acute erythroleukemia patients had higher total bone marrow blasts, lower platelets …
Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
Domingo-Claros A, Larriba I, Rozman M, Irriguible D, Vallespí T, Aventin A, Ayats R, Millá F, Solé F, Florensa L, Gallart M, Tuset E, Lopez C, Woessner S. Domingo-Claros A, et al. Haematologica. 2002 Feb;87(2):148-53. Haematologica. 2002. PMID: 11836165 Review.
The recent WHO classification has a category of acute myeloid leukemia not otherwise categorized, which includes acute erythroid leukemia (M6) of two subtypes: M6a-erythroleukemia (erythroid/myeloid) and M6b-pure erythroid leuke …
The recent WHO classification has a category of acute myeloid leukemia not otherwise categorized, which includes acute …
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia.
Olopade OI, Thangavelu M, Larson RA, Mick R, Kowal-Vern A, Schumacher HR, Le Beau MM, Vardiman JW, Rowley JD. Olopade OI, et al. Blood. 1992 Dec 1;80(11):2873-82. Blood. 1992. PMID: 1450412 Free article.
We have performed a retrospective analysis of the clinical, morphologic, and cytogenetic findings in 26 patients diagnosed between January 1969 and September 1991 with acute erythroblastic leukemia de novo (EL or AML-M6). Clonal chromosomal abnormalities were …
We have performed a retrospective analysis of the clinical, morphologic, and cytogenetic findings in 26 patients diagnosed between January 1 …
270 results